Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes

Key Takeaways Novo Nordisk won FDA approval for Awiqli, a once-weekly basal insulin for adults with type II diabetes.Awiqli showed strong HbA1c reduction in the phase IIIa ONWARDS studies vs. daily basal insulin.NVO plans a U.S. launch of the FlexTouch device in the second half of 2026 after global approvals.Novo Nordisk (NVO) announced that the FDA has approved Awiqli injection as the first and only once-weekly, long-acting basal insulin icodec for adults with type II diabetes (T2D). The therapy is indicat ...